BIO Comments Re: Comments on Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors
May 17, 2016
Dear Dr. Taichman:
The Biotechnology Innovation Organization (BIO) is pleased to offer the following comments on Sharing Clinical Trial Data: A proposal from the International Committee of Medical Journal Editors (“ICMJE”) (“the Proposal”). 1
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.
General Comments
BIO member companies are committed to improving human health through the development of innovative therapies. We strongly support research that aims to improve human health through better drug development and recognize that responsibly sharing our clinical trial data can help to advance such research, while reinforcing public confidence in the safety and efficacy of our medicines. As such, we share the underlying goals of ICMJE in setting forth a policy to “increase confidence and trust in the conclusions drawn from clinical trials,” “enable the independent confirmation of results,” and “foster the development and testing of new hypotheses.”2 Even though most BIO member companies are small, prerevenue enterprises that operate with limited resources, and evaluation of requests for data may divert resources from their core mission of developing innovative therapies, BIO members recognize the value of supporting qualified external medical and scientific research via data sharing...
Download Full Comments Below
2016-04-18 ICMJE Clinical Trial Data Sharing Draft Comments FINAL
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a…
The meeting of global trade ministers at the World Trade Organization’s 13th Ministerial Conference in Abu Dhabi offers an important opportunity to build on and strengthen the open and rules-based international trading system to support better…
Dear Dr. Taichman:
The Biotechnology Innovation Organization (BIO) is pleased to offer the following comments on Sharing Clinical Trial Data: A proposal from the International Committee of Medical Journal Editors (“ICMJE”) (“the Proposal”). 1
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.
General Comments
BIO member companies are committed to improving human health through the development of innovative therapies. We strongly support research that aims to improve human health through better drug development and recognize that responsibly sharing our clinical trial data can help to advance such research, while reinforcing public confidence in the safety and efficacy of our medicines. As such, we share the underlying goals of ICMJE in setting forth a policy to “increase confidence and trust in the conclusions drawn from clinical trials,” “enable the independent confirmation of results,” and “foster the development and testing of new hypotheses.”2 Even though most BIO member companies are small, prerevenue enterprises that operate with limited resources, and evaluation of requests for data may divert resources from their core mission of developing innovative therapies, BIO members recognize the value of supporting qualified external medical and scientific research via data sharing...